Compare Ginkgo Bioworks Holdings Inc (DNA) vs Honeywell International Inc (HON) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.

DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.

Honeywell Technologies (HON) trades at $246.19, up 2.26% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, and the company has completed strategic divestitures to focus on automation. Key financials show a P/E of 9.47, net income margin of 21.58%, and robust cash flow from operations of $6.41B in 2025. The stock is near its consensus price target of $320.54, indicating potential upside.

Outlook is positive due to earnings momentum and portfolio simplification, but risks include integration challenges from spinoffs and macroeconomic sensitivity. Institutional sentiment is bullish with 66.7% buy ratings. Investors should monitor execution of growth strategies in building automation and aerospace segments for sustained performance.